Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

INTRODUCTION More than 50% of patients treated with chimeric antigen receptor (CAR)–T
cells for B cell malignancies develop progressive disease after CAR therapy, and these …

Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell
haematologic malignancies. The manufacturing of these T cells typically involves their …

Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …

Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable
activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure …

Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

While many drugs are effective at reducing the relapse frequency of multiple sclerosis (MS),
there is an unmet need for treatments that slow neurodegeneration resulting from secondary …

The development of immunotherapies over the past decade has resulted in a paradigm shift
in the treatment of cancer. However, the majority of patients do not benefit from …

Cytotoxic T cell immunity in response to chronic infections and tumours is maintained by a
specialized population of CD8+ T cells that exhibit hallmarks of both exhausted and memory …